For research use only. Not for therapeutic Use.
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane. Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Catalog Number | A000070 |
CAS Number | 57-96-5 |
Synonyms | G-28315, NSC 75925 |
Molecular Formula | C23H20N2O3S |
Purity | ≥95% |
Target | Endogenous Metabolite |
Solubility | Soluble in DMSO |
Storage | Store at -20°C |
IUPAC Name | 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione |
InChI | InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2 |
InChIKey | MBGGBVCUIVRRBF-UHFFFAOYSA-N |
SMILES | C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4 |
Reference | 1: Kerdpin O, Elliot DJ, Mackenzie PI, Miners JO. Sulfinpyrazone 2: Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate 3: Yang ML, Huang TS, Lee Y, Lu FJ. Free radical scavenging properties of 4: He M, Rettie AE, Neal J, Trager WF. Metabolism of sulfinpyrazone sulfide and 5: Caforio AL, Gambino A, Tona F, Feltrin G, Marchini F, Pompei E, Testolin L, 6: Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P. 7: Drago F, La Manna C, Emmi I, Marino A. Effects of sulfinpyrazone on retinal 8: Walls M, Goral S, Stone W. Acute renal failure due to sulfinpyrazone. Am J Med <br> 10: He M, Kunze KL, Trager WF. Inhibition of (S)-warfarin metabolism by |